CLINICAL INFECTIOUS DISEASES-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1065212, encodeId=6d30106521261, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：传染病;结核 经验分享：8月份投的，一个月给了审稿意见，写的大修给了两个月时间，两个审稿人的态度都很positive, 问题也不多，一审返修第二天就接受了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a18a5557008, createdName=ms1000001905132543, createdTime=Sat Oct 30 09:30:21 CST 2021, time=2021-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960714, encodeId=b5f3960e14e7, content=请教：这个杂志可以有两个第一作者么？看到杂志把通讯作者放在第一位，那怎么显示谁是第一作者呢？就只能有一个通讯作者吗？求各位大神指教，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca55486655, createdName=Dr. ER, createdTime=Mon Apr 26 19:59:52 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528174, encodeId=00115281e45e, content=该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c751609628, createdName=ifmorethanten, createdTime=Thu Oct 13 09:45:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229210, encodeId=450b122921052, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：10月底投稿，次年1月初给了小修，两位审稿人很专业，除了修改意见之外问了很多他们感兴趣的问题，修回一个半月后接收，一周后在线发表原始的manuscript，后面的清样阶段时间很长，两三个月后才会上线正式版。 本来是传染病第三的杂志，但是因为新冠的文章太多，其他老牌传染病杂志膨胀的厉害，目前掉到第六，但仍然是传染病领域的老牌权威杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1f6c2337148, createdName=12281bbem87(暂无昵称), createdTime=Tue Jun 28 17:05:39 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088856, encodeId=5cb11088856d7, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088855, encodeId=da7e108885563, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588536, encodeId=41295885361d, content=你到底说的是哪个期刊？ifmorethanten 2016-10-13 发表:: SCI(2015)：8.736 SCI(2014)：8.886 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。ifmorethanten 2016-10-13 09:45:00 发表: 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, beContent=ifmorethanten 2016-10-13 发表:: SCI(2015)：8.736 SCI(2014)：8.886 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e78f2081038, createdName=superzhanli_83184254, createdTime=Thu Apr 09 00:00:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113689, encodeId=d6bf2113689d6, content=想问问undereview是送审了吗已经undereview8天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3c38243251, createdName=ms8000000803184690, createdTime=Wed Feb 08 22:23:19 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588998, encodeId=bb7658899802, content=单位新冠研究的文章，感觉效率非常高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQATvGgiaMKNVvxNf0yhLsYOhNPiaHgTUl6xdntTzXT1Y5MHTStTB4Yrumicp8swRtzmIamzRj80yiaIgn/0, createdBy=e504105739, createdName=jimmyyin, createdTime=Thu Apr 16 00:00:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588905, encodeId=6933588905a7, content=文章字数要求少于2500, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f132335532, createdName=1227c63cm48(暂无昵称), createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=)]

2021-10-30 ms1000001905132543

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：传染病;结核
经验分享：8月份投的，一个月给了审稿意见，写的大修给了两个月时间，两个审稿人的态度都很positive, 问题也不多，一审返修第二天就接受了

131 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=1065212, encodeId=6d30106521261, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：传染病;结核 经验分享：8月份投的，一个月给了审稿意见，写的大修给了两个月时间，两个审稿人的态度都很positive, 问题也不多，一审返修第二天就接受了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a18a5557008, createdName=ms1000001905132543, createdTime=Sat Oct 30 09:30:21 CST 2021, time=2021-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960714, encodeId=b5f3960e14e7, content=请教：这个杂志可以有两个第一作者么？看到杂志把通讯作者放在第一位，那怎么显示谁是第一作者呢？就只能有一个通讯作者吗？求各位大神指教，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca55486655, createdName=Dr. ER, createdTime=Mon Apr 26 19:59:52 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528174, encodeId=00115281e45e, content=该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c751609628, createdName=ifmorethanten, createdTime=Thu Oct 13 09:45:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229210, encodeId=450b122921052, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：10月底投稿，次年1月初给了小修，两位审稿人很专业，除了修改意见之外问了很多他们感兴趣的问题，修回一个半月后接收，一周后在线发表原始的manuscript，后面的清样阶段时间很长，两三个月后才会上线正式版。 本来是传染病第三的杂志，但是因为新冠的文章太多，其他老牌传染病杂志膨胀的厉害，目前掉到第六，但仍然是传染病领域的老牌权威杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1f6c2337148, createdName=12281bbem87(暂无昵称), createdTime=Tue Jun 28 17:05:39 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088856, encodeId=5cb11088856d7, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088855, encodeId=da7e108885563, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588536, encodeId=41295885361d, content=你到底说的是哪个期刊？ifmorethanten 2016-10-13 发表:: SCI(2015)：8.736 SCI(2014)：8.886 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。ifmorethanten 2016-10-13 09:45:00 发表: 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, beContent=ifmorethanten 2016-10-13 发表:: SCI(2015)：8.736 SCI(2014)：8.886 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e78f2081038, createdName=superzhanli_83184254, createdTime=Thu Apr 09 00:00:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113689, encodeId=d6bf2113689d6, content=想问问undereview是送审了吗已经undereview8天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3c38243251, createdName=ms8000000803184690, createdTime=Wed Feb 08 22:23:19 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588998, encodeId=bb7658899802, content=单位新冠研究的文章，感觉效率非常高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQATvGgiaMKNVvxNf0yhLsYOhNPiaHgTUl6xdntTzXT1Y5MHTStTB4Yrumicp8swRtzmIamzRj80yiaIgn/0, createdBy=e504105739, createdName=jimmyyin, createdTime=Thu Apr 16 00:00:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588905, encodeId=6933588905a7, content=文章字数要求少于2500, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f132335532, createdName=1227c63cm48(暂无昵称), createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=)]

2021-04-26 Dr. ER

请教：这个杂志可以有两个第一作者么？看到杂志把通讯作者放在第一位，那怎么显示谁是第一作者呢？就只能有一个通讯作者吗？求各位大神指教，谢谢！

126 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1065212, encodeId=6d30106521261, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：传染病;结核 经验分享：8月份投的，一个月给了审稿意见，写的大修给了两个月时间，两个审稿人的态度都很positive, 问题也不多，一审返修第二天就接受了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a18a5557008, createdName=ms1000001905132543, createdTime=Sat Oct 30 09:30:21 CST 2021, time=2021-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960714, encodeId=b5f3960e14e7, content=请教：这个杂志可以有两个第一作者么？看到杂志把通讯作者放在第一位，那怎么显示谁是第一作者呢？就只能有一个通讯作者吗？求各位大神指教，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca55486655, createdName=Dr. ER, createdTime=Mon Apr 26 19:59:52 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528174, encodeId=00115281e45e, content=该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c751609628, createdName=ifmorethanten, createdTime=Thu Oct 13 09:45:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229210, encodeId=450b122921052, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：10月底投稿，次年1月初给了小修，两位审稿人很专业，除了修改意见之外问了很多他们感兴趣的问题，修回一个半月后接收，一周后在线发表原始的manuscript，后面的清样阶段时间很长，两三个月后才会上线正式版。 本来是传染病第三的杂志，但是因为新冠的文章太多，其他老牌传染病杂志膨胀的厉害，目前掉到第六，但仍然是传染病领域的老牌权威杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1f6c2337148, createdName=12281bbem87(暂无昵称), createdTime=Tue Jun 28 17:05:39 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088856, encodeId=5cb11088856d7, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088855, encodeId=da7e108885563, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588536, encodeId=41295885361d, content=你到底说的是哪个期刊？ifmorethanten 2016-10-13 发表:: SCI(2015)：8.736 SCI(2014)：8.886 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。ifmorethanten 2016-10-13 09:45:00 发表: 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, beContent=ifmorethanten 2016-10-13 发表:: SCI(2015)：8.736 SCI(2014)：8.886 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e78f2081038, createdName=superzhanli_83184254, createdTime=Thu Apr 09 00:00:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113689, encodeId=d6bf2113689d6, content=想问问undereview是送审了吗已经undereview8天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3c38243251, createdName=ms8000000803184690, createdTime=Wed Feb 08 22:23:19 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588998, encodeId=bb7658899802, content=单位新冠研究的文章，感觉效率非常高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQATvGgiaMKNVvxNf0yhLsYOhNPiaHgTUl6xdntTzXT1Y5MHTStTB4Yrumicp8swRtzmIamzRj80yiaIgn/0, createdBy=e504105739, createdName=jimmyyin, createdTime=Thu Apr 16 00:00:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588905, encodeId=6933588905a7, content=文章字数要求少于2500, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f132335532, createdName=1227c63cm48(暂无昵称), createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=)]

2016-10-13 ifmorethanten

该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。

575 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1065212, encodeId=6d30106521261, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：传染病;结核 经验分享：8月份投的，一个月给了审稿意见，写的大修给了两个月时间，两个审稿人的态度都很positive, 问题也不多，一审返修第二天就接受了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a18a5557008, createdName=ms1000001905132543, createdTime=Sat Oct 30 09:30:21 CST 2021, time=2021-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960714, encodeId=b5f3960e14e7, content=请教：这个杂志可以有两个第一作者么？看到杂志把通讯作者放在第一位，那怎么显示谁是第一作者呢？就只能有一个通讯作者吗？求各位大神指教，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca55486655, createdName=Dr. ER, createdTime=Mon Apr 26 19:59:52 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528174, encodeId=00115281e45e, content=该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c751609628, createdName=ifmorethanten, createdTime=Thu Oct 13 09:45:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229210, encodeId=450b122921052, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：10月底投稿，次年1月初给了小修，两位审稿人很专业，除了修改意见之外问了很多他们感兴趣的问题，修回一个半月后接收，一周后在线发表原始的manuscript，后面的清样阶段时间很长，两三个月后才会上线正式版。 本来是传染病第三的杂志，但是因为新冠的文章太多，其他老牌传染病杂志膨胀的厉害，目前掉到第六，但仍然是传染病领域的老牌权威杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1f6c2337148, createdName=12281bbem87(暂无昵称), createdTime=Tue Jun 28 17:05:39 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088856, encodeId=5cb11088856d7, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088855, encodeId=da7e108885563, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588536, encodeId=41295885361d, content=你到底说的是哪个期刊？ifmorethanten 2016-10-13 发表:: SCI(2015)：8.736 SCI(2014)：8.886 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。ifmorethanten 2016-10-13 09:45:00 发表: 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, beContent=ifmorethanten 2016-10-13 发表:: SCI(2015)：8.736 SCI(2014)：8.886 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e78f2081038, createdName=superzhanli_83184254, createdTime=Thu Apr 09 00:00:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113689, encodeId=d6bf2113689d6, content=想问问undereview是送审了吗已经undereview8天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3c38243251, createdName=ms8000000803184690, createdTime=Wed Feb 08 22:23:19 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588998, encodeId=bb7658899802, content=单位新冠研究的文章，感觉效率非常高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQATvGgiaMKNVvxNf0yhLsYOhNPiaHgTUl6xdntTzXT1Y5MHTStTB4Yrumicp8swRtzmIamzRj80yiaIgn/0, createdBy=e504105739, createdName=jimmyyin, createdTime=Thu Apr 16 00:00:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588905, encodeId=6933588905a7, content=文章字数要求少于2500, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f132335532, createdName=1227c63cm48(暂无昵称), createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=)]

2022-06-28 12281bbem87(暂无昵称)

审稿速度:6.0 | 投稿命中率:25.0
经验分享：10月底投稿，次年1月初给了小修，两位审稿人很专业，除了修改意见之外问了很多他们感兴趣的问题，修回一个半月后接收，一周后在线发表原始的manuscript，后面的清样阶段时间很长，两三个月后才会上线正式版。
本来是传染病第三的杂志，但是因为新冠的文章太多，其他老牌传染病杂志膨胀的厉害，目前掉到第六，但仍然是传染病领域的老牌权威杂志。

78 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1065212, encodeId=6d30106521261, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：传染病;结核 经验分享：8月份投的，一个月给了审稿意见，写的大修给了两个月时间，两个审稿人的态度都很positive, 问题也不多，一审返修第二天就接受了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a18a5557008, createdName=ms1000001905132543, createdTime=Sat Oct 30 09:30:21 CST 2021, time=2021-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960714, encodeId=b5f3960e14e7, content=请教：这个杂志可以有两个第一作者么？看到杂志把通讯作者放在第一位，那怎么显示谁是第一作者呢？就只能有一个通讯作者吗？求各位大神指教，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca55486655, createdName=Dr. ER, createdTime=Mon Apr 26 19:59:52 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528174, encodeId=00115281e45e, content=该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c751609628, createdName=ifmorethanten, createdTime=Thu Oct 13 09:45:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229210, encodeId=450b122921052, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：10月底投稿，次年1月初给了小修，两位审稿人很专业，除了修改意见之外问了很多他们感兴趣的问题，修回一个半月后接收，一周后在线发表原始的manuscript，后面的清样阶段时间很长，两三个月后才会上线正式版。 本来是传染病第三的杂志，但是因为新冠的文章太多，其他老牌传染病杂志膨胀的厉害，目前掉到第六，但仍然是传染病领域的老牌权威杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1f6c2337148, createdName=12281bbem87(暂无昵称), createdTime=Tue Jun 28 17:05:39 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088856, encodeId=5cb11088856d7, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088855, encodeId=da7e108885563, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588536, encodeId=41295885361d, content=你到底说的是哪个期刊？ifmorethanten 2016-10-13 发表:: SCI(2015)：8.736 SCI(2014)：8.886 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。ifmorethanten 2016-10-13 09:45:00 发表: 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, beContent=ifmorethanten 2016-10-13 发表:: SCI(2015)：8.736 SCI(2014)：8.886 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e78f2081038, createdName=superzhanli_83184254, createdTime=Thu Apr 09 00:00:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113689, encodeId=d6bf2113689d6, content=想问问undereview是送审了吗已经undereview8天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3c38243251, createdName=ms8000000803184690, createdTime=Wed Feb 08 22:23:19 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588998, encodeId=bb7658899802, content=单位新冠研究的文章，感觉效率非常高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQATvGgiaMKNVvxNf0yhLsYOhNPiaHgTUl6xdntTzXT1Y5MHTStTB4Yrumicp8swRtzmIamzRj80yiaIgn/0, createdBy=e504105739, createdName=jimmyyin, createdTime=Thu Apr 16 00:00:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588905, encodeId=6933588905a7, content=文章字数要求少于2500, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f132335532, createdName=1227c63cm48(暂无昵称), createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=)]

2021-12-28 MS68862005

如何判断两种药物之间是协同作用还是相加作用？

106 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1065212, encodeId=6d30106521261, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：传染病;结核 经验分享：8月份投的，一个月给了审稿意见，写的大修给了两个月时间，两个审稿人的态度都很positive, 问题也不多，一审返修第二天就接受了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a18a5557008, createdName=ms1000001905132543, createdTime=Sat Oct 30 09:30:21 CST 2021, time=2021-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960714, encodeId=b5f3960e14e7, content=请教：这个杂志可以有两个第一作者么？看到杂志把通讯作者放在第一位，那怎么显示谁是第一作者呢？就只能有一个通讯作者吗？求各位大神指教，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca55486655, createdName=Dr. ER, createdTime=Mon Apr 26 19:59:52 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528174, encodeId=00115281e45e, content=该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c751609628, createdName=ifmorethanten, createdTime=Thu Oct 13 09:45:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229210, encodeId=450b122921052, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：10月底投稿，次年1月初给了小修，两位审稿人很专业，除了修改意见之外问了很多他们感兴趣的问题，修回一个半月后接收，一周后在线发表原始的manuscript，后面的清样阶段时间很长，两三个月后才会上线正式版。 本来是传染病第三的杂志，但是因为新冠的文章太多，其他老牌传染病杂志膨胀的厉害，目前掉到第六，但仍然是传染病领域的老牌权威杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1f6c2337148, createdName=12281bbem87(暂无昵称), createdTime=Tue Jun 28 17:05:39 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088856, encodeId=5cb11088856d7, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088855, encodeId=da7e108885563, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588536, encodeId=41295885361d, content=你到底说的是哪个期刊？ifmorethanten 2016-10-13 发表:: SCI(2015)：8.736 SCI(2014)：8.886 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。ifmorethanten 2016-10-13 09:45:00 发表: 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, beContent=ifmorethanten 2016-10-13 发表:: SCI(2015)：8.736 SCI(2014)：8.886 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e78f2081038, createdName=superzhanli_83184254, createdTime=Thu Apr 09 00:00:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113689, encodeId=d6bf2113689d6, content=想问问undereview是送审了吗已经undereview8天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3c38243251, createdName=ms8000000803184690, createdTime=Wed Feb 08 22:23:19 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588998, encodeId=bb7658899802, content=单位新冠研究的文章，感觉效率非常高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQATvGgiaMKNVvxNf0yhLsYOhNPiaHgTUl6xdntTzXT1Y5MHTStTB4Yrumicp8swRtzmIamzRj80yiaIgn/0, createdBy=e504105739, createdName=jimmyyin, createdTime=Thu Apr 16 00:00:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588905, encodeId=6933588905a7, content=文章字数要求少于2500, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f132335532, createdName=1227c63cm48(暂无昵称), createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=)]

2021-12-27 乌云背后的幸福线

上传文章有什么要求？

106 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1065212, encodeId=6d30106521261, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：传染病;结核 经验分享：8月份投的，一个月给了审稿意见，写的大修给了两个月时间，两个审稿人的态度都很positive, 问题也不多，一审返修第二天就接受了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a18a5557008, createdName=ms1000001905132543, createdTime=Sat Oct 30 09:30:21 CST 2021, time=2021-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960714, encodeId=b5f3960e14e7, content=请教：这个杂志可以有两个第一作者么？看到杂志把通讯作者放在第一位，那怎么显示谁是第一作者呢？就只能有一个通讯作者吗？求各位大神指教，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca55486655, createdName=Dr. ER, createdTime=Mon Apr 26 19:59:52 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528174, encodeId=00115281e45e, content=该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c751609628, createdName=ifmorethanten, createdTime=Thu Oct 13 09:45:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229210, encodeId=450b122921052, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：10月底投稿，次年1月初给了小修，两位审稿人很专业，除了修改意见之外问了很多他们感兴趣的问题，修回一个半月后接收，一周后在线发表原始的manuscript，后面的清样阶段时间很长，两三个月后才会上线正式版。 本来是传染病第三的杂志，但是因为新冠的文章太多，其他老牌传染病杂志膨胀的厉害，目前掉到第六，但仍然是传染病领域的老牌权威杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1f6c2337148, createdName=12281bbem87(暂无昵称), createdTime=Tue Jun 28 17:05:39 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088856, encodeId=5cb11088856d7, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088855, encodeId=da7e108885563, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588536, encodeId=41295885361d, content=你到底说的是哪个期刊？ifmorethanten 2016-10-13 发表:: SCI(2015)：8.736 SCI(2014)：8.886 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。ifmorethanten 2016-10-13 09:45:00 发表: 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, beContent=ifmorethanten 2016-10-13 发表:: SCI(2015)：8.736 SCI(2014)：8.886 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e78f2081038, createdName=superzhanli_83184254, createdTime=Thu Apr 09 00:00:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113689, encodeId=d6bf2113689d6, content=想问问undereview是送审了吗已经undereview8天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3c38243251, createdName=ms8000000803184690, createdTime=Wed Feb 08 22:23:19 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588998, encodeId=bb7658899802, content=单位新冠研究的文章，感觉效率非常高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQATvGgiaMKNVvxNf0yhLsYOhNPiaHgTUl6xdntTzXT1Y5MHTStTB4Yrumicp8swRtzmIamzRj80yiaIgn/0, createdBy=e504105739, createdName=jimmyyin, createdTime=Thu Apr 16 00:00:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588905, encodeId=6933588905a7, content=文章字数要求少于2500, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f132335532, createdName=1227c63cm48(暂无昵称), createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=)]

2020-04-09 superzhanli_83184254

你到底说的是哪个期刊？ifmorethanten 2016-10-13 发表::
SCI(2015)：8.736 SCI(2014)：8.886 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。ifmorethanten 2016-10-13 09:45:00 发表:
该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。

ifmorethanten 2016-10-13 发表:: SCI(2015)：8.736 SCI(2014)：8.886 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。

216 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1065212, encodeId=6d30106521261, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：传染病;结核 经验分享：8月份投的，一个月给了审稿意见，写的大修给了两个月时间，两个审稿人的态度都很positive, 问题也不多，一审返修第二天就接受了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a18a5557008, createdName=ms1000001905132543, createdTime=Sat Oct 30 09:30:21 CST 2021, time=2021-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960714, encodeId=b5f3960e14e7, content=请教：这个杂志可以有两个第一作者么？看到杂志把通讯作者放在第一位，那怎么显示谁是第一作者呢？就只能有一个通讯作者吗？求各位大神指教，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca55486655, createdName=Dr. ER, createdTime=Mon Apr 26 19:59:52 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528174, encodeId=00115281e45e, content=该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c751609628, createdName=ifmorethanten, createdTime=Thu Oct 13 09:45:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229210, encodeId=450b122921052, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：10月底投稿，次年1月初给了小修，两位审稿人很专业，除了修改意见之外问了很多他们感兴趣的问题，修回一个半月后接收，一周后在线发表原始的manuscript，后面的清样阶段时间很长，两三个月后才会上线正式版。 本来是传染病第三的杂志，但是因为新冠的文章太多，其他老牌传染病杂志膨胀的厉害，目前掉到第六，但仍然是传染病领域的老牌权威杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1f6c2337148, createdName=12281bbem87(暂无昵称), createdTime=Tue Jun 28 17:05:39 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088856, encodeId=5cb11088856d7, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088855, encodeId=da7e108885563, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588536, encodeId=41295885361d, content=你到底说的是哪个期刊？ifmorethanten 2016-10-13 发表:: SCI(2015)：8.736 SCI(2014)：8.886 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。ifmorethanten 2016-10-13 09:45:00 发表: 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, beContent=ifmorethanten 2016-10-13 发表:: SCI(2015)：8.736 SCI(2014)：8.886 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e78f2081038, createdName=superzhanli_83184254, createdTime=Thu Apr 09 00:00:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113689, encodeId=d6bf2113689d6, content=想问问undereview是送审了吗已经undereview8天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3c38243251, createdName=ms8000000803184690, createdTime=Wed Feb 08 22:23:19 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588998, encodeId=bb7658899802, content=单位新冠研究的文章，感觉效率非常高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQATvGgiaMKNVvxNf0yhLsYOhNPiaHgTUl6xdntTzXT1Y5MHTStTB4Yrumicp8swRtzmIamzRj80yiaIgn/0, createdBy=e504105739, createdName=jimmyyin, createdTime=Thu Apr 16 00:00:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588905, encodeId=6933588905a7, content=文章字数要求少于2500, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f132335532, createdName=1227c63cm48(暂无昵称), createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=)]

2023-02-08 ms8000000803184690

想问问undereview是送审了吗已经undereview8天了

71 0

[GetPortalCommentsPageByObjectIdResponse(id=1065212, encodeId=6d30106521261, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：传染病;结核 经验分享：8月份投的，一个月给了审稿意见，写的大修给了两个月时间，两个审稿人的态度都很positive, 问题也不多，一审返修第二天就接受了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a18a5557008, createdName=ms1000001905132543, createdTime=Sat Oct 30 09:30:21 CST 2021, time=2021-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960714, encodeId=b5f3960e14e7, content=请教：这个杂志可以有两个第一作者么？看到杂志把通讯作者放在第一位，那怎么显示谁是第一作者呢？就只能有一个通讯作者吗？求各位大神指教，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca55486655, createdName=Dr. ER, createdTime=Mon Apr 26 19:59:52 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528174, encodeId=00115281e45e, content=该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c751609628, createdName=ifmorethanten, createdTime=Thu Oct 13 09:45:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229210, encodeId=450b122921052, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：10月底投稿，次年1月初给了小修，两位审稿人很专业，除了修改意见之外问了很多他们感兴趣的问题，修回一个半月后接收，一周后在线发表原始的manuscript，后面的清样阶段时间很长，两三个月后才会上线正式版。 本来是传染病第三的杂志，但是因为新冠的文章太多，其他老牌传染病杂志膨胀的厉害，目前掉到第六，但仍然是传染病领域的老牌权威杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1f6c2337148, createdName=12281bbem87(暂无昵称), createdTime=Tue Jun 28 17:05:39 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088856, encodeId=5cb11088856d7, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088855, encodeId=da7e108885563, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588536, encodeId=41295885361d, content=你到底说的是哪个期刊？ifmorethanten 2016-10-13 发表:: SCI(2015)：8.736 SCI(2014)：8.886 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。ifmorethanten 2016-10-13 09:45:00 发表: 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, beContent=ifmorethanten 2016-10-13 发表:: SCI(2015)：8.736 SCI(2014)：8.886 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e78f2081038, createdName=superzhanli_83184254, createdTime=Thu Apr 09 00:00:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113689, encodeId=d6bf2113689d6, content=想问问undereview是送审了吗已经undereview8天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3c38243251, createdName=ms8000000803184690, createdTime=Wed Feb 08 22:23:19 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588998, encodeId=bb7658899802, content=单位新冠研究的文章，感觉效率非常高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQATvGgiaMKNVvxNf0yhLsYOhNPiaHgTUl6xdntTzXT1Y5MHTStTB4Yrumicp8swRtzmIamzRj80yiaIgn/0, createdBy=e504105739, createdName=jimmyyin, createdTime=Thu Apr 16 00:00:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588905, encodeId=6933588905a7, content=文章字数要求少于2500, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f132335532, createdName=1227c63cm48(暂无昵称), createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=)]

2020-04-16 jimmyyin

单位新冠研究的文章，感觉效率非常高

196 0

[GetPortalCommentsPageByObjectIdResponse(id=1065212, encodeId=6d30106521261, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：传染病;结核 经验分享：8月份投的，一个月给了审稿意见，写的大修给了两个月时间，两个审稿人的态度都很positive, 问题也不多，一审返修第二天就接受了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a18a5557008, createdName=ms1000001905132543, createdTime=Sat Oct 30 09:30:21 CST 2021, time=2021-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960714, encodeId=b5f3960e14e7, content=请教：这个杂志可以有两个第一作者么？看到杂志把通讯作者放在第一位，那怎么显示谁是第一作者呢？就只能有一个通讯作者吗？求各位大神指教，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca55486655, createdName=Dr. ER, createdTime=Mon Apr 26 19:59:52 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528174, encodeId=00115281e45e, content=该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c751609628, createdName=ifmorethanten, createdTime=Thu Oct 13 09:45:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229210, encodeId=450b122921052, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：10月底投稿，次年1月初给了小修，两位审稿人很专业，除了修改意见之外问了很多他们感兴趣的问题，修回一个半月后接收，一周后在线发表原始的manuscript，后面的清样阶段时间很长，两三个月后才会上线正式版。 本来是传染病第三的杂志，但是因为新冠的文章太多，其他老牌传染病杂志膨胀的厉害，目前掉到第六，但仍然是传染病领域的老牌权威杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1f6c2337148, createdName=12281bbem87(暂无昵称), createdTime=Tue Jun 28 17:05:39 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088856, encodeId=5cb11088856d7, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088855, encodeId=da7e108885563, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588536, encodeId=41295885361d, content=你到底说的是哪个期刊？ifmorethanten 2016-10-13 发表:: SCI(2015)：8.736 SCI(2014)：8.886 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。ifmorethanten 2016-10-13 09:45:00 发表: 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, beContent=ifmorethanten 2016-10-13 发表:: SCI(2015)：8.736 SCI(2014)：8.886 该杂志只允许一个通讯作者，多课题组合作文章投稿时请注意。不要引起麻烦。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e78f2081038, createdName=superzhanli_83184254, createdTime=Thu Apr 09 00:00:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113689, encodeId=d6bf2113689d6, content=想问问undereview是送审了吗已经undereview8天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3c38243251, createdName=ms8000000803184690, createdTime=Wed Feb 08 22:23:19 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588998, encodeId=bb7658899802, content=单位新冠研究的文章，感觉效率非常高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQATvGgiaMKNVvxNf0yhLsYOhNPiaHgTUl6xdntTzXT1Y5MHTStTB4Yrumicp8swRtzmIamzRj80yiaIgn/0, createdBy=e504105739, createdName=jimmyyin, createdTime=Thu Apr 16 00:00:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588905, encodeId=6933588905a7, content=文章字数要求少于2500, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f132335532, createdName=1227c63cm48(暂无昵称), createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=)]

2020-04-15 1227c63cm48(暂无昵称)

文章字数要求少于2500

227 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务